BiotechTube
Home/Britecyte/Samson Tom
ST

Samson Tom

President, CEO, Co-Founder

Britecyte

Therapeutic Areas

Metabolic DiseasesOsteoarthritisSoft Tissue ReconstructionAesthetic Medicine

Britecyte Pipeline

DrugIndicationPhase
LiposanaAdipose defects / Soft tissue reconstructionCommercial
LipodermaFacial volume restoration / AestheticsCommercial
Metabolic Diseases ProgramMetabolic syndrome, Diabetes, Fatty Liver DiseasePre-clinical
Osteoarthritis ProgramOsteoarthritisPre-clinical

Leadership Team at Britecyte

AD
Alla Danilkovitch
Founder, Chief Scientific Officer
MS
Molly Saunders
Vice President, Sales and Marketing
PF
Peter Friedli
Chairman, Co-Founder
View full Britecyte profile